Use of intravenous neuraminidase inhibitors during the 2009 pandemic: Results from population-based surveillance

JAMA

Volumn 306, Issue 2, 2011, Pages 160-162

  Fry, Alicia M ^a   Pérez, Alejandro ^a   Finelli, Lyn ^a  

^a CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

OSELTAMIVIR; PERAMIVIR; ZANAMIVIR;

2009 H1N1 INFLUENZA; ADULT; CHILD; DRUG DOSE REGIMEN; HEALTH SURVEY; HOSPITALIZATION; HUMAN; INTENSIVE CARE UNIT; KIDNEY DISEASE; LETTER; MAJOR CLINICAL STUDY; OBESITY; POPULATION RESEARCH; PRIORITY JOURNAL;

EID: 79960167539     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2011.950     Document Type: Letter

References (5)

1. Updated interim recommendations for the use of antiviral medications in the treatment and prevention of influenza for the 2009-2010 season. Centers for Disease Control and Prevention. http://www.cdc.gov/h1n1flu/recommendations.htm. Accessed January 31, 2010.
2. Birnkrant D, Cox E. The Emergency Use Authorization of peramivir for treatment of 2009 H1N1 influenza. N Engl J Med. 2009;361(23):2204-2207.
3. Emergency use authorization of peramivir IV fact sheet for health care providers. Food and Drug Administration. http://www.fda.gov/downloads/Drugs/ DrugSafety/PostmarketDrugSafetyInormationforPatientsandProviders/UCM187811.pdf. Accessed January 6, 2011.
4. Dawood F, Fiore A, Kamimoto L, et al. Burden of seasonal influenza hospitalization in children, United States, 2003 to 2008. J Pediatr. 2010;157(5):808-814.
5. Dao CN, Kamimoto L, Nowell M, et al. Adult hospitalizations for laboratory-positive influenza during the 2005-2006 through 2007-2009 seasons in the United States. J Infect Dis. 2010;202(6):881-888.